A Randomized, Double-blinded, Placebo-controlled, Single Center, Dose Escalation, Phase I Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects
Latest Information Update: 26 Aug 2020
At a glance
- Drugs MT 921 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Medytox
Most Recent Events
- 11 Apr 2019 New trial record